Rapport Therapeutics, Inc. (RAPP) · Nov 4, 2026 · Earnings
Beat — GAAP EPS -$0.84 vs approximately -$1.20 consensus
Rapport Therapeutics’ Q3 earnings beat consensus and cash runway reaches 2029, but the key bipolar trial win was already disclosed.
Rapport is a clinical-stage neuroscience biotech advancing RAP-219 through Phase 3 epilepsy trials while preparing a bipolar-mania Phase 3 program. The bipolar Phase 2 success was already announced on October 20, 2026, so this filing mainly confirms that progress, reports the quarter, and updates the financing position.
The quarter beat the limited financial benchmark. GAAP diluted EPS was $0.84 per share in loss versus a published consensus of roughly $1.20 in loss, a meaningful beat, although the company remains loss-making and operating expenses rose as clinical programs advanced. The consensus estimate was publicly listed at approximately -$1.20 per share.
| Metric | Q3 2026 | Q3 2025 | Consensus |
|---|---|---|---|
| Net loss (Statement of Operations) | $40.2M (+49.4%) | -$26.9M | |
| Diluted EPS (Statement of Operations) | -$0.84 | -$0.71 | ~-$1.20 |
| R&D expense (Statement of Operations) | $34.3M (+54.0%) | $22.3M | |
| Cash and short-term investments (Cash Position) | $395.0M | $436.1M* |
*June 30, 2026 comparison.
The important clinical result is confirmation, not a fresh surprise. RAP-219 met both bipolar-mania Phase 2 endpoints, including a 3.1-point placebo-adjusted YMRS improvement, but that result was already public before this 8-K. 〔0〕 The filing does reinforce that the company is moving toward an FDA End-of-Phase 2 discussion in the first quarter of 2027 and two planned Phase 3 trials in the second half of 2027.
The balance sheet materially reduces near-term execution pressure. October’s equity-and-convertible-debt financing generated approximately $410.7 million of net proceeds, while the November ATM added approximately $10 million. Management now expects funding through the end of 2029, giving Rapport room to run the FOS Phase 3 program, prepare bipolar Phase 3, and advance earlier pipeline assets. 〔1〕
The trade-off is higher spending and capital usage as the pipeline scales. Net loss increased to $40.2 million from $26.9 million a year earlier, while R&D rose to $34.3 million from $22.3 million as FOS Phase 3 and bipolar development progressed. That is expected for the company’s stage, but it means the financing—not internal cash generation—is what extends the runway.
Bottom line: This is a modestly positive earnings update because the loss was narrower than consensus and funding now reaches 2029. It does not materially upgrade the clinical story, because the main bipolar win was already disclosed; the next genuinely new test is the FDA interaction in early 2027.
FDA End-of-Phase 2 meeting, Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!